Merck KGaA (MRK) News Today €138.20 -0.25 (-0.18%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Merck closes exclusive global license agreement for LM-299 from LaNova MedicinesDecember 20 at 3:39 PM | markets.businessinsider.comBMO Capital Downgrades Merck (MRK)December 20 at 3:39 PM | msn.comMerck Reports Topline Data From Phase 3 Trials Of Doravirine + Islatravir To Treat HIV-1 InfectionDecember 19 at 9:05 AM | markets.businessinsider.comMerck: FDA To Review BLA For Clesrovimab - Quick FactsDecember 17, 2024 | markets.businessinsider.comMerck announces approval of KEYTRUDA in China in combination with chemotherapyDecember 16, 2024 | markets.businessinsider.comMerck announces CHMP opinion recommending conditional approval of WeliregDecember 13, 2024 | markets.businessinsider.comMerck gets positive EU regulatory opinion for WeliregDecember 13, 2024 | msn.comBoulder drug discovery co. attracts Merck as an investorDecember 11, 2024 | bizjournals.comIs Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?December 11, 2024 | msn.comWhy former Merck VP left big biotech for this Seattle startupDecember 10, 2024 | bizjournals.comMerck says Phase 3 KEYLYNK-001 trial met primary endpointDecember 10, 2024 | markets.businessinsider.comMerck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian CancerDecember 10, 2024 | finance.yahoo.comMerck reports mixed results from Keytruda ovarian cancer studyDecember 10, 2024 | msn.comWhy Merck & Co. (MRK) Is Among the Best Affordable Stocks to Buy Right NowDecember 6, 2024 | msn.comMerck (NYSE:MRK) Will Pay A Larger Dividend Than Last Year At $0.81December 5, 2024 | finance.yahoo.comHere’s What is Powering Merck & Co.’s (MRK) Earnings GrowthDecember 5, 2024 | msn.comHSBC upgrades Merck stock to Buy on 2025 opportunitiesDecember 5, 2024 | msn.comMerck gets FDA Breakthrough Therapy designation for sac-TMTDecember 3, 2024 | msn.comWhy Is Merck & Co., Inc. (MRK) Among the Stocks Ray Dalio’s Bridgewater Is Crazy About?December 2, 2024 | msn.comMerck KGaA (ETR:MRK) Trading 0.8% Higher - What's Next?Merck KGaA (ETR:MRK) Shares Up 0.8% - Still a Buy?November 27, 2024 | marketbeat.comMerck Phase 3 study of Winrevair in PAH meets primary endpointNovember 25, 2024 | msn.comMerck Reports Positive Topline Results From The Phase 3 ZENITH Study Evaluating WINREVAIR In PAHNovember 25, 2024 | markets.businessinsider.comMerck recommends rejection of TRC Capital’s ‘mini-tender’ offerNovember 23, 2024 | markets.businessinsider.comMerck recommends rejection of TRC Capital’s ‘mini-tender’ offerNovember 23, 2024 | markets.businessinsider.comMerck Announces Approval For WELIREG In China - Quick FactsNovember 22, 2024 | markets.businessinsider.comMerck elects Surendralal Karsanbhai to board of directorsNovember 22, 2024 | markets.businessinsider.comMerck-marketed asthma drug linked to psychiatric issues: reportNovember 22, 2024 | seekingalpha.comGoldman Sachs: Merck & Co., Inc. (MRK) Is A Top Growth Investor StockNovember 22, 2024 | msn.comMerck target upped at Jefferies after ‘important win’ with subcutaneous KeytrudaNovember 21, 2024 | markets.businessinsider.comMerck raises quarterly dividend to 81c from 77c per shareNovember 20, 2024 | markets.businessinsider.comMerck announces ‘positive’ results from Phase 3 MK-3475A-D77 trialNovember 19, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on Merck KGaA (0O14)November 18, 2024 | markets.businessinsider.comIs Merck & Co., Inc. (MRK) the Best Immunotherapy Stock to Buy Now?November 18, 2024 | msn.comMerck receives CHMP opinion recommending approval of KeytrudaNovember 15, 2024 | markets.businessinsider.comMerck KGaA Q3 earnings rise faster than expected on lower costsNovember 14, 2024 | reuters.comMerck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter MissNovember 14, 2024 | wsj.comMerck KGaA's Cell-Tumor Drug Gets Positive Results in Late-Stage TrialNovember 12, 2024 | morningstar.comMerck & Co., Inc. (MRK) Makes It On UBS’ List Of Stocks For The AI, Growth & Low Rates EraNovember 8, 2024 | msn.comMerck price target lowered to $140 from $145 at Deutsche BankNovember 6, 2024 | markets.businessinsider.comMerck KGaA: A Continued Long-Term Upside Despite Some LagNovember 5, 2024 | seekingalpha.comMerck & Co. Stock: Is Wall Street Bullish or Bearish?November 4, 2024 | msn.comMerck price target lowered to $120 from $140 at BofANovember 1, 2024 | markets.businessinsider.comMerck Reports Steady Q3 2024 Growth Amid ChallengesNovember 1, 2024 | markets.businessinsider.comMerck reports Q3 adjusted EPS $1.57, consensus $1.50October 31, 2024 | markets.businessinsider.comMerck (MRK) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | msn.comMerck & Co Inc. Q3 Profit FallsOctober 31, 2024 | markets.businessinsider.comMerck earnings top estimates amid solid demand for Keytruda cancer drugOctober 31, 2024 | msn.comMerck Cuts FY24 Earnings View, Narrows Sales Forecast After Weak Q3 Earnings - UpdateOctober 31, 2024 | markets.businessinsider.comMerck’s Q3 earnings beat estimates, but company lowers guidanceOctober 31, 2024 | marketwatch.comMerck Q3 Earnings Preview: Focus on Winrevair and KeytrudaOctober 30, 2024 | msn.com Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. MRK Media Mentions By Week MRK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRK News Sentiment▼0.360.60▲Average Medical News Sentiment MRK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRK Articles This Week▼53▲MRK Articles Average Week Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MorphoSys News Today ad pepper media International News Today Genfit News Today Evotec News Today Siemens Healthineers News Today Bayer Aktiengesellschaft News Today Fresenius Medical Care News Today Carl Zeiss Meditec News Today Gerresheimer News Today CompuGroup Medical SE & Co. KGaA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ETR:MRK) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRK Stock Alerts